Last reviewed · How we verify

NCT06762509: WD

The Clinical Study of Botulinum Toxin Type A Injection in the Treatment of Wilson Disease

Completed Last updated 15 January 2025
What this trial tests

trial testing Botulinum toxin type A in Wilson Disease in 60 participants. Completed in 1 January 2024.

Timeline
1 December 2016
Primary endpoint
1 December 2023
1 January 2024

Quick facts

Lead sponsorThe First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
StatusCompleted
Study typeOBSERVATIONAL
Enrollment60
Start date1 December 2016
Primary completion1 December 2023
Estimated completion1 January 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

Who can join

Adults 15 to 65, any sex, with Wilson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In order to expand the treatment of Wilson disease and improve the quality of life of patients with Wilson's disease, the clinical effect of botulinum toxin type A injection on Wilson's disease was discussed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Botulinum toxin type A

Trials testing the same drug.

Other recruiting trials for Wilson Disease

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06762509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing